AIDS Research and Treatment 1995–2004,” International Journal of Cancer, vol. 122, no. 10, pp. 2260–2265, 2008. [40] R. Yamada, T. Sasagawa, L. W. Kirumbi et al., “Human papil- lomavirus infection and cervical abnormalities in Nairobi, Kenya, an area with a high prevalence of human immunod- eﬁciency virus infection,” Journal of Medical Virology, vol. 80, no. 5, pp. 847–855, 2008. [41] D. B. Blossom, R. H. Beigi, J. J. Farrell et al., “Human papillomavirus genotypes associated with cervical cytologic abnormalities and HIV infection in Ugandan women,” Journal of Medical Virology, vol. 79, no. 6, pp. 758–765, 2007. [42] J. R. Moodley, D. Constant, M. Hoﬀman et al., “Human papil- lomavirus prevalence, viral load and pre-cancerous lesions of the cervix in women initiating highly active antiretroviral therapy in South Africa: a cross-sectional study,” BMC Cancer, vol. 9, article no. 275, 2009. [43] A. T. Davis, H. Chakraborty, L. Flowers, and M. B. Mosunjac, “Cervical dysplasia in women infected with the human immunodeﬁciency virus (HIV): a correlation with HIV viral load and CD4+ count,” Gynecologic Oncology, vol. 80, no. 3, pp. 350–354, 2001. [44] A. Chalermchockcharoenkit, K. Sirimai, and P. Chaisilwat- tana, “High prevalence of cervical squamous cell abnor- malities among HIV-infected women with immunological AIDS-deﬁning illnesses,” Journal of Obstetrics and Gynaecology Research, vol. 32, no. 3, pp. 324–329, 2006. [45] P. Schuman, S. E. Ohmit, R. S. Klein et al., “Longitudinal study of cervical squamous intraepithelial lesions in human immunodeﬁdency virus (HIV)-seropositive and at-risk HIV- seronegative women,” Journal of Infectious Diseases, vol. 188, no. 1, pp. 128–136, 2003. [46] K. V. Shah, L. Solomon, R. Daniel, S. Cohn, and D. Vlahov, “Comparison of PCR and hybrid capture methods for detec- tion of human papillomavirus in injection drug-using women at high risk of human immunodeﬁciency virus infection,” Journal of Clinical Microbiology, vol. 35, no. 2, pp. 517–519, 1997. [47] S. D. Vernon, W. C. Reeves, K. A. Clancy et al., “A longitudinal study of human papillomavirus DNA detection in human immunodeﬁciency virus type 1-seropositive and -seronegative women,” Journal of Infectious Diseases, vol. 169, no. 5, pp. 1108–1112, 1994. [48] X. W. Sun, L. Kuhn, T. V. Ellerbrock, M. A. Chiasson, T. J. Bush, and T. C. Wright, “Human papillomavirus infection in women infected with the human immunodeﬁciency virus,” New England Journal of Medicine, vol. 337, no. 19, pp. 1343– 1349, 1997. [49] C. Hankins, N. Lapointe, and S. Walmsley, “Participation in clinical trials among women living with HIV in Canada,” CMAJ, vol. 159, no. 11, pp. 1359–1365, 1998. [50] F. B. Lillo, D. Ferrari, F. Veglia et al., “Human papillomavirus infection and associated cervical disease in human immun- odeﬁciency virus-infected women: eﬀect of highly active antiretroviral therapy,” Journal of Infectious Diseases, vol. 184, no. 5, pp. 547–551, 2001. 7